Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
Status:
Recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
The goal of this Phase 2 trial is to evaluate a non-surgical bladder-preserving treatment
mode which consists of induction chemotherapy plus anti-programmed cell death protein 1
(anti-PD-1) therapy followed by radiotherapy plus concurrent anti-PD-1 therapy. The main
questions it aims to answer are: (i) whether the anti-PD-1 antibody, toripalimab, is
effective in treating muscle-invasive bladder cancer (MIBC), when combined with
chemoradiation; (ii) whether toripalimab is safe in combination with chemoradiation.
Participants will receive 3 cycles of induction treatment containing chemotherapy with
gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive
disease will receive radical radiotherapy plus 2 cycles of concurrent toripalimab.